Mouse Anti-ITGB3 Recombinant Antibody (A698) (CBMAB-AP4043LY)

Integrin Subunit Beta 3

The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling. [provided by RefSeq, Jul 2008]

Integrin Subunit Beta 3

CSB-MA110588

Activation of protein kinase activityManual Assertion Based On ExperimentIMP:BHF-UCL
Angiogenesis involved in wound healingManual Assertion Based On ExperimentTAS:BHF-UCL
Apolipoprotein A-I-mediated signaling pathwayManual Assertion Based On ExperimentIMP:UniProtKB
Apoptotic cell clearanceManual Assertion Based On ExperimentIGI:BHF-UCL
Blood coagulationManual Assertion Based On ExperimentTAS:ProtInc
Cell adhesionManual Assertion Based On ExperimentTAS:ProtInc
Cell adhesion mediated by integrinManual Assertion Based On ExperimentIDA:UniProtKB
Cell migrationManual Assertion Based On ExperimentIBA:GO_Central
Cell-matrix adhesionManual Assertion Based On ExperimentIMP:UniProtKB
Cell-substrate adhesionManual Assertion Based On ExperimentIMP:UniProtKB
Heterotypic cell-cell adhesionManual Assertion Based On ExperimentIMP:UniProtKB
Integrin-mediated signaling pathwayManual Assertion Based On ExperimentHDA:UniProtKB
Mesodermal cell differentiationManual Assertion Based On ExperimentIEP:UniProtKB
Negative chemotaxisManual Assertion Based On ExperimentIMP:UniProtKB
Negative regulation of lipid storageManual Assertion Based On ExperimentIMP:BHF-UCL
Negative regulation of lipid transportManual Assertion Based On ExperimentIMP:BHF-UCL
Negative regulation of lipoprotein metabolic processManual Assertion Based On ExperimentIMP:BHF-UCL
Negative regulation of low-density lipoprotein receptor activityManual Assertion Based On ExperimentIMP:BHF-UCL
Negative regulation of macrophage derived foam cell differentiationManual Assertion Based On ExperimentIMP:BHF-UCL
Platelet activationManual Assertion Based On ExperimentIMP:UniProtKB
Platelet aggregationManual Assertion Based On ExperimentIMP:UniProtKB
Positive regulation of endothelial cell migrationManual Assertion Based On ExperimentIMP:BHF-UCL
Positive regulation of endothelial cell proliferationManual Assertion Based On ExperimentIMP:BHF-UCL
Positive regulation of peptidyl-tyrosine phosphorylationManual Assertion Based On ExperimentIMP:BHF-UCL
Positive regulation of protein phosphorylationManual Assertion Based On ExperimentTAS:BHF-UCL
Positive regulation of vascular endothelial growth factor receptor signaling pathwayManual Assertion Based On ExperimentTAS:BHF-UCL
Regulation of bone resorptionManual Assertion Based On ExperimentTAS:BHF-UCL
Regulation of postsynaptic neurotransmitter receptor internalizationManual Assertion Based On ExperimentIDA:SynGO
Regulation of protein localizationISS:UniProtKB
Regulation of serotonin uptakeISS:UniProtKB
Smooth muscle cell migrationManual Assertion Based On ExperimentIMP:BHF-UCL
Substrate adhesion-dependent cell spreadingManual Assertion Based On ExperimentIDA:UniProtKB
Tube developmentManual Assertion Based On ExperimentTAS:BHF-UCL
Viral entry into host cellManual Assertion Based On ExperimentIMP:UniProtKB
Wound healing1 PublicationIC:BHF-UCL

Cell membrane; Cell projection, lamellipodium membrane; Cell junction, focal adhesion; Cell junction, synapse, postsynaptic cell membrane; Cell junction, synapse

Glanzmann thrombasthenia 2 (GT2):
A form of Glanzmann thrombasthenia, a disorder characterized by failure of platelet aggregation, absent or diminished clot retraction, and mucocutaneous bleeding of mild-to-moderate severity. Glanzmann thrombasthenia has been classified into clinical types I and II. In type I, platelets show absence of glycoprotein IIb-IIIa complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express glycoprotein IIb-IIIa complexes at reduced levels, have detectable amounts of fibrinogen, and have low or moderate clot retraction capability.
Bleeding disorder, platelet-type, 24 (BDPLT24):
An autosomal dominant disorder of platelet production characterized by congenital macrothrombocytopenia and platelet anisocytosis. Affected individuals may have no or only mildly increased bleeding tendency.

Extracellular: 27-718
Helical: 719-741
Cytoplasmic: 742-788

Phosphorylated on tyrosine residues in response to thrombin-induced platelet aggregation. Probably involved in outside-in signaling. A peptide (AA 740-762) is capable of binding GRB2 only when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation of Thr-779 inhibits SHC binding.